Yale University

Regeneron Pharmaceuticals, Inc.

Institute for Research in Biomedicine (irb)

Emory University

Institute for Research in Biomedicine

Madhav Dhodapkar

Andrew J Murphy

George D Yancopoulos

Sean Stevens

Richard A Flavell

Markus G Manz

Till Strowig

Chiara Borsotti

Kavita Dhodapkar

Venkata Naga Chandrasekhar Boddupalli

Genetically modified non-human animals are provided that may be used to model human hematopoietic cell development, function, or disease. The genetically modified non-human animals comprise a nucleic acid encoding human IL-6 operably linked to an IL-6 promoter. In some instances, the genetically modified non-human animal expressing human IL-6 also expresses at least one of human M-CSF, human IL-3, human GM-CSF, human SIRPa or human TPO. In some instances, the genetically modified non-human animal is immunodeficient. In some such instances, the genetically modified non-human animal is engrafted with healthy or diseased human hematopoietic cells. Also provided are methods for using the subject genetically modified non-human animals in modeling human hematopoietic cell development, function, and/or disease, as well as reagents and kits thereof that find use in making the subject genetically modified non-human animals and/or practicing the subject methods.

Genetically modified non-human animals and methods of use thereof

The present disclosure includes compositions, methods, and uses for a subset of T cells, SP T (T) cells, which display a quiescent (G0) phenotype. Aspects of the disclosure include methods for obtaining and mobilizing Tcells in a subject. Other aspects include methods of adoptive cell transfer in a subject utilizing Tcells.

Methods to mobilize tissue resident cells for adoptive t cell therapy

The present invention relates to predictors of a cancer patient's responsiveness to immunotherapy for cancer.

Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer

The present invention provides a peptide having an amino acid sequence as set forth in SEQ ID NOs: 1 through 95 and any combination thereof. The peptide or combination of peptides possess OCT4 specific inducibility. The peptide or combination of peptides can further be used as a vaccine.

Immunogenic epitopes as targets for universal cancer vaccines

Growing community of inventors

New Haven, CT, United States of America

Madhav Dhodapkar